FGFR3 and neoplasm: Using a Gaussian kernel to smooth the outcomes at Day 25, we see that anti-FGFR3 monotherapy does decrease Day 25 tumor burden for tumors with mutants present, as illustrated by the red peaks of the PDFs lying to the left of the black peaks in the middle and right column of Figure 4A.